Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
Publication
, Journal Article
Kumar, SK; Callander, NS; Alsina, M; Atanackovic, D; Biermann, JS; Chandler, JC; Costello, C; Faiman, M; Fung, HC; Gasparetto, C; Godby, K ...
Published in: J Natl Compr Canc Netw
February 2017
Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-related complications include hypercalcemia, renal insufficiency, anemia, and infections. The NCCN Multiple Myeloma Panel members have developed guidelines for the management of patients with various plasma cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, multiple myeloma, systemic light chain amyloidosis, and Waldenström's macroglobulinemia. The recommendations specific to the diagnosis and treatment of patients with newly diagnosed MM are discussed in this article.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
February 2017
Volume
15
Issue
2
Start / End Page
230 / 269
Location
United States
Related Subject Headings
- Treatment Outcome
- Stem Cell Transplantation
- Standard of Care
- Serologic Tests
- Radiotherapy, Adjuvant
- Positron Emission Tomography Computed Tomography
- Oncology & Carcinogenesis
- Myeloma Proteins
- Multiple Myeloma
- Medical Oncology
Citation
APA
Chicago
ICMJE
MLA
NLM
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., … Kumar, R. (2017). Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(2), 230–269. https://doi.org/10.6004/jnccn.2017.0023
Kumar, Shaji K., Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J Sybil Biermann, Jason C. Chandler, Caitlin Costello, et al. “Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 15, no. 2 (February 2017): 230–69. https://doi.org/10.6004/jnccn.2017.0023.
Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, et al. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Feb;15(2):230–69.
Kumar, Shaji K., et al. “Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw, vol. 15, no. 2, Feb. 2017, pp. 230–69. Pubmed, doi:10.6004/jnccn.2017.0023.
Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Feb;15(2):230–269.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
February 2017
Volume
15
Issue
2
Start / End Page
230 / 269
Location
United States
Related Subject Headings
- Treatment Outcome
- Stem Cell Transplantation
- Standard of Care
- Serologic Tests
- Radiotherapy, Adjuvant
- Positron Emission Tomography Computed Tomography
- Oncology & Carcinogenesis
- Myeloma Proteins
- Multiple Myeloma
- Medical Oncology